Artiva Halts Cell Therapy After Two Patient Deaths, Cuts Workforce 94%
Artiva Biotherapeutics said it would halt development of its experimental cell therapy for certain autoimmune conditions after two deaths among patients being tested on the treatment. Its shares fell 30% in premarket trading.
Story updates
12:21:06 PM UTC
SquawkNews
BUZZ-Artiva股价下跌，此前该公司因患者死亡而暂停了细胞疗法研发 10月27日 - ** 药物开发商 Artiva Biotherapeutics（ARTV.O）的股价在盘前交易中下跌 29.
Artiva Biotherapeutics NASDAQ:ARTV said on Tuesday it would halt the development of its experimental cell therapy for certain autoimmune conditions after two deaths among patients who were being tested on the treatment, sending its shares down 30% in premarket trading.The therapy developer is also…